북미의 동맥 수술용 지혈 실란트 시장 규모, 점유율 및 동향 분석 보고서 : 제품별, 용도별 및 부문별 예측(2026-2033년)

North America Hemostatic Sealants In Arterial Surgery Market Summary

The North America hemostatic sealants in arterial surgery market size was estimated at USD 100.0 million in 2025 and is projected to grow from USD 102.3 million in 2026 to USD 119.6 million by 2033, at a CAGR of 2.3% from 2026 to 2033. The growth is driven by the increasing demand for effective intraoperative bleeding management during complex vascular procedures.

Arterial surgeries such as aortic aneurysm repair, peripheral bypass grafting, carotid endarterectomy, and vascular reconstruction frequently involve significant bleeding risks due to high-pressure blood flow and the widespread use of anticoagulant therapies among cardiovascular patients. As a result, hospitals and vascular surgeons are increasingly adopting topical hemostatic sealants as adjunctive technologies to enhance surgical precision, reduce blood loss, and improve procedural outcomes.

The market is benefiting from the growing clinical emphasis on reducing operative complications, shortening procedure duration, and minimizing the need for blood transfusions or surgical reinterventions. Hemostatic sealants are increasingly used to reinforce vascular anastomoses, seal needle-hole bleeding, and support suture-line integrity during arterial repair procedures. Their ability to achieve rapid hemostasis has made them particularly valuable in high-risk surgeries involving fragile vascular tissue, calcified arteries, or elderly patients with multiple comorbidities.

A major factor supporting market expansion is the strengthening body of clinical evidence validating the effectiveness of sealants in vascular surgery. In May 2024, an updated Cochrane systematic review titled "The role of sealants for achieving anastomotic hemostasis in vascular surgery" evaluated 24 randomized controlled trials involving more than 2,300 vascular surgery patients. The analysis demonstrated that sealant use significantly reduced time to hemostasis compared with conventional approaches such as manual compression, gelatin sponges, and oxidized cellulose-based agents. The review also highlighted lower rates of hemostatic intervention failure, reinforcing surgeon confidence in sealant-assisted vascular closure techniques.

Commercial adoption across North America continues to expand, driven by the widespread use of advanced fibrin-based and synthetic sealant products, including TISSEEL, EVICEL, BioGlue, COSEAL, and SURGIFLO. These products are increasingly used in hospitals and vascular surgery centers due to their rapid polymerization, strong tissue adhesion, ease of application, and compatibility with both open and minimally invasive surgical approaches.

The rising prevalence of cardiovascular diseases across the U.S. and Canada is further contributing to procedural growth in arterial surgery. Increasing incidences of peripheral artery disease, abdominal aortic aneurysms, diabetes-associated vascular complications, and traumatic vascular injuries are leading to higher volumes of vascular interventions. In parallel, the rapidly aging population across North America is increasing the number of elderly patients requiring arterial reconstruction and bypass procedures, thereby expanding the demand for advanced intraoperative bleeding control solutions.

Minimally invasive aortic valve replacement (MIAVR) procedures are also gaining strong adoption across cardiac centers. A study published by the National Library of Medicine reported that MIAVR significantly reduces postoperative pain, blood transfusion requirements, respiratory complications, wound infections, ICU stays, and hospitalization duration compared to conventional sternotomy procedures. The study further highlighted improved cosmetic outcomes, earlier mobilization, and lower overall surgical trauma.

North America Hemostatic Sealants In Arterial Surgery Market Report Segmentation

This report forecasts revenue growth at regional and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. Forthis study, Grand View Research has segmented the North America hemostatic sealants in arterial surgery market report based on product, application, disease indication, end use, and country:

• Product Outlook (Revenue, USD Unit, 2021 - 2033)
• Fibrin-Based Sealants
• Synthetic/Polymer-Based Sealants
• Combination Hemostats & Sealants
• Application Outlook (Revenue, USD Unit, 2021 - 2033)
• Arterial Surgery With Graft Replacement
• Arterial Repair/Reconstruction Without Graft
• Disease Indication Outlook (Revenue, USD Unit, 2021 - 2033)
• Aortic Aneurysms
• Peripheral Artery Disease
• Carotid Artery Disease
• Others
• End Use Outlook (Revenue, USD Unit, 2021 - 2033)
• Public Hospitals
• Private Hospitals
• Country Outlook (Revenue, USD Unit, 2021 - 2033)
• U.S.
• Canada

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Application
  • 1.2.3. Disease Indication
  • 1.2.4. End Use
  • 1.2.5. Country scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Product outlook
  • 2.2.2. Application outlook
  • 2.2.3. Disease Indicatio outlook
  • 2.2.4. End Use outlook
  • 2.2.5. Country outlook
• 2.3. Competitive Insights

Chapter 3. North America Hemostatic Sealants In Arterial Surgery Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. North America Hemostatic Sealants In Arterial Surgery Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. North America Hemostatic Sealants In Arterial Surgery Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. North America Hemostatic Sealants In Arterial Surgery Market: Product Movement Analysis
• 4.3. North America Hemostatic Sealants In Arterial Surgery Market by Product Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 4.5. Fibrin-Based Sealants
  • 4.5.1. Fibrin-Based Sealants Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Synthetic/Polymer-Based Sealants
  • 4.6.1. Synthetic/Polymer-Based Sealants Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Combination Hemostats & Sealants
  • 4.7.1. Combination Hemostats & Sealants Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. North America Hemostatic Sealants In Arterial Surgery Market: Application Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. North America Hemostatic Sealants In Arterial Surgery Market: Application Movement Analysis
• 5.3. North America Hemostatic Sealants In Arterial Surgery Market by Application Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 5.5. Arterial Surgery With Graft Replacement
  • 5.5.1. Arterial Surgery With Graft Replacement Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Arterial Repair/Reconstruction Without Graft
  • 5.6.1. Arterial Repair/Reconstruction Without Graft Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. North America Hemostatic Sealants In Arterial Surgery Market: Disease Indication Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. North America Hemostatic Sealants In Arterial Surgery Market: Disease Indication Movement Analysis
• 6.3. North America Hemostatic Sealants In Arterial Surgery Market by Disease Indication Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 6.5. Aortic Aneurysms
  • 6.5.1. Aortic Aneurysms Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Peripheral Artery Disease
  • 6.6.1. Peripheral Artery Disease Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Carotid Artery Disease
  • 6.7.1. Carotid Artery Disease Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Others
  • 6.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. North America Hemostatic Sealants In Arterial Surgery Market: End Use Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. North America Hemostatic Sealants In Arterial Surgery Market: End Use Movement Analysis
• 7.3. North America Hemostatic Sealants In Arterial Surgery Market by End Use Outlook (USD Million)
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 7.5. Public Hospitals
  • 7.5.1. Public Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Private Hospitals
  • 7.6.1. Private Hospitals Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. North America Hemostatic Sealants In Arterial Surgery Market: Regional Estimates & Trend Analysis

• 8.1. Regional Dashboard
• 8.2. Regional North America Hemostatic Sealants In Arterial Surgery Market Movement Analysis
• 8.3. North America Hemostatic Sealants In Arterial Surgery Market: Regional Estimates & Trend Analysis by Product & Application
• 8.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
• 8.5. North America
  • 8.5.1. North America Hemostatic Sealants In Arterial Surgery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. U.S.
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Reimbursement scenario
    • 8.5.2.5. U.S. Hemostatic Sealants In Arterial Surgery Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. Canada
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Reimbursement scenario
    • 8.5.3.5. Canada Hemostatic Sealants In Arterial Surgery Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Key Company Profiles
  • 9.2.1. Ethicon
    • 9.2.1.1. Company Overview
    • 9.2.1.2. Financial Performance
    • 9.2.1.3. Product Benchmarking
    • 9.2.1.4. Strategic Initiatives
  • 9.2.2. Baxter International
    • 9.2.2.1. Company Overview
    • 9.2.2.2. Financial Performance
    • 9.2.2.3. Product Benchmarking
    • 9.2.2.4. Strategic Initiatives
  • 9.2.3. Corza Medical
    • 9.2.3.1. Company Overview
    • 9.2.3.2. Financial Performance
    • 9.2.3.3. Product Benchmarking
    • 9.2.3.4. Strategic Initiatives
  • 9.2.4. Integra LifeSciences Corporation
    • 9.2.4.1. Company Overview
    • 9.2.4.2. Financial Performance
    • 9.2.4.3. Product Benchmarking
    • 9.2.4.4. Strategic Initiatives
  • 9.2.5. Artivion
    • 9.2.5.1. Company Overview
    • 9.2.5.2. Financial Performance
    • 9.2.5.3. Product Benchmarking
    • 9.2.5.4. Strategic Initiatives
  • 9.2.6. Becton, Dickinson and Company (BD)
    • 9.2.6.1. Company Overview
    • 9.2.6.2. Financial Performance
    • 9.2.6.3. Product Benchmarking
    • 9.2.6.4. Strategic Initiatives
  • 9.2.7. Teleflex
    • 9.2.7.1. Company Overview
    • 9.2.7.2. Financial Performance
    • 9.2.7.3. Product Benchmarking
    • 9.2.7.4. Strategic Initiatives